ad image

BRAF-Mutant Melanoma

1 / 1
Pierre Fabre
Positive Opinion

Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in adult patients with advanced BRAF-mutant melanoma

Pierre Fabre

PR-M08-18-NI-008Aug 02, 2018
Pierre Fabre
Clinical Data

Pierre Fabre and Array BioPharma Announce COLUMBUS Phase 3 Study Overall Survival Results in BRAF-Mutant Melanoma Will Be Presented at 2018 ASCO Annual Meeting

Pierre Fabre

PR-M05-18-NI-076May 21, 2018
1 / 1